Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial-Reference-Cited by-同舟云学术

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

Published:2023-05 Issue:10389 Volume:401 Page:1655-1668
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Shitara Kohei,Lordick Florian,Bang Yung-Jue,Enzinger Peter,Ilson David,Shah Manish A,Van Cutsem Eric,Xu Rui-Hua,Aprile Giuseppe,Xu Jianming,Chao Joseph,Pazo-Cid Roberto,Kang Yoon-Koo,Yang Jianning,Moran Diarmuid,Bhattacharya Pranob,Arozullah Ahsan,Park Jung Wook,Oh Mok,Ajani Jaffer A

Publisher

Elsevier BV

Subject

General Medicine

Reference25 articles.

1. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019;Lancet,2020

2. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021;Wang;Cancer Commun (Lond),2021

3. Gastric cancer;Van Cutsem;Lancet,2016

4. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition);Gastric Cancer,2023

5. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010

Cited by 217 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Effect of antiemetics on zolbetuximab-induced gastric injury and emesis in ferrets;Journal of Pharmacological Sciences;2024-11

3. Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach;Modern Pathology;2024-11

4. Expression profiles of cadherin 17 and claudin 18.2 in comparison with peptide hormonal expression in pancreatic neuroendocrine tumours: Implications for targeted immunotherapy;Pathology - Research and Practice;2024-10

5. A narrative review on advances in neoadjuvant immunotherapy for esophageal cancer: Molecular biomarkers and future directions;International Journal of Cancer;2024-09-14